Compare Pfizer Inc (PFE) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Vanguard Growth Index Fund ETF — how do they compare? Pfizer Inc trades at $27.75 (market cap $159.59B), while Vanguard Growth Index Fund ETF trades at $91.99 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 2.4× Pfizer Inc's market cap, and Pfizer Inc pays a 6.14% dividend while Vanguard Growth Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| PFE | VUG | |
|---|---|---|
Market Cap | $159.59B | $384.60B |
Volume | 30,937,010 | 4,760,473 |
Sector | Health | Sector/Thematic |
52-Week High | $29.02 | $92.64 |
52-Week Low | $23.67 | $70.00 |
Typical Hold Time | 158 Days | 47 Days |
Enterprise Value | $211.09B | — |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
VUG trades at $92.42, down 0.24% with bullish technical signals from moving averages but bearish oscillators suggesting potential overbought conditions. The ETF maintains strong long-term performance with 12% average annual returns since inception, though current RSI levels indicate near-term caution. Recent news highlights VUG's concentration in mega-cap technology stocks like Nvidia, Apple, and Microsoft, which comprise over 36% of holdings.
Long-term growth prospects remain favorable given VUG's historical outperformance and low 0.03% expense ratio. However, significant concentration risk in technology sector and elevated RSI levels present near-term headwinds. The ETF's value proposition centers on cost-efficient exposure to large-cap growth stocks for investors with multi-decade time horizons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
